Abstract LB-016: Characteristics of the pretreatment tumor microenvironment may influence clinical response in patients with refractory large B cell lymphoma treated with axicabtagene ciloleucel (axi-cel) in the pivotal ZUMA-1

Introduction : Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 CAR T cell therapy approved by the US Food and Drug Administration for patients with relapsed or refractory large B cell lymphoma with ≥2 prior systemic therapies. Results from the primary analysis of ZUMA-1 demonstrated an objective response rate of 82%, with 54% complete responses (Neelapu u0026 Locke et al. N Engl J Med . 2017). Grade ≥3 cytokine release syndrome and neurologic events occurred at 13% and 28%, respectively, and were generally reversible. Building on previous reports of CAR treatment-related tumor microenvironment (TME) changes (Galon et al. ASCO 2017. #3025), here, we examine associations between the pretreatment TME and clinical outcomes. Methods : Patients received axi-cel (target dose, 2.0 × 10 6 cells/kg) in phases 1 and 2 of ZUMA-1 (NCT02348216). Baseline tumor biopsy samples were analyzed by digital gene expression (NanoString TM ). Prespecified bioinformatics algorithm and cutoffs were applied to immune-mediated tumor regression genes (Immunosign ® ; Galon et al. Immunity. 2013), which included T cell-specific (effector T cell, Th1) genes, interferon pathway-related genes, chemokines, cytokines, and immune checkpoints. Expression analysis and scoring examined potential associations between TME features and response. A broader, hypothesis-generating analysis was performed using all PanCancer Immune Profiling Panel genes (770 genes) by NanoString TM . Fisher9s exact test and Wilcoxon signed rank test with multiple test correction by false discovery rate (Benjamini-Hochberg) were used. Results : Tumor samples from all immediate pre-treatment biopsy samples that passed quality control (6 nonresponders; 21 responders) were analyzed. Pretreatment TME Immunosign21 scores were elevated in responders vs nonresponders. Responses were seen in 18/20 patients (90%) with high and 3/7 patients (43%) with low Immunosign21 scores. Immune-related genes from the Immunosign21 or Pan Cancer profile that showed higher expression at baseline in responders included CTLA4, CD3γ, CD3e, CD27, and ICOSL. Genes with lower expression in responders at baseline included MHC class II genes and cancer-testis antigens. Additional correlative analyses between TME characteristics and CAR T cell activity will be presented. Conclusions : Increased baseline expression of TME genes related to T cell activity, along with decreased expression of MHC class II and cancer testis antigens (CTAs), may be associated with a response to axi-cel. These findings should be validated in ongoing and subsequent studies. Citation Format: John M. Rossi, Jerome Galon, Sarah Turcan, Corinne Danan, Frederick L. Locke, Sattva S. Neelapu, David B. Miklos, Caron A. Jacobson, Lazaros J. Lekakis, Yi Lin, Armin Ghobadi, William Y. Go, Adrian Bot. Characteristics of the pretreatment tumor microenvironment may influence clinical response in patients with refractory large B cell lymphoma treated with axicabtagene ciloleucel (axi-cel) in the pivotal ZUMA-1 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr LB-016.